Angiostomy Cannula Market Analysis & Forecast: 2026-2033
Angiostomy Cannula Market is estimated to be valued at USD 216.7 Mn in 2026 and is expected to reach USD 350.2 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033. The Angiostomy Cannula Market is witnessing steady growth driven by rising cardiovascular and interventional surgical procedures, increasing geriatric population, and continuous advancement in minimally invasive vascular access technologies. According to WHO clinical guidance on cardiovascular disease management and CDC reports on chronic heart conditions, demand for reliable vascular access devices continues to rise globally. In 2026, journals such as Journal of Vascular Access highlight improved biocompatible polymer cannulas reducing infection risks and improving procedural safety. Associations like the American Heart Association emphasize growing use in cardiac support procedures. In 2026, BD and Edwards Lifesciences reported enhanced FDA-cleared cannula-based delivery systems, reflecting innovation in precision vascular interventions and expanding hospital adoption worldwide.
The growing incidences of product approvals are a major factor leading to the high demand for angiostomy cannulas. For instance, on April 3, 2023, Anika Therapeutics, Inc., a global joint preservation company focused on early intervention orthopedics, announced that it had received an additional 510(k) clearance from US FDA for Tactoset Injectable Bone Substitute. Tactoset is an injectable, settable, calcium phosphate-based bone graft substitute that incorporates Anika Therapeutics, Inc.’s core hyaluronic acid (HA) technology. The HA component of Tactoset makes the product highly flowable, easily injectable, and able to interdigitate into trabecular bone architecture with improved handling characteristics compared to competitive products. Once injected, Tactoset hardens and mimics the properties of normal trabecular bone initially before remodeling into healthy bone over time.
The increasing product launches to invent newer, technologically advanced cannulas can drive the growth of the global angiostosmy cannula market. For instance, in August 2020, 3B Medical, a medical device company, introduced the Freedom X oxygen nasal cannula, intended to address nose irritation, which is a common complaint from oxygen patients.
Increasing technology advancement in cannula design and expansion in emerging market is creating opportunity for the global angiostomy cannula market growth over the forecast period. Innovation in materials and design is improving safety, efficiency, and adoption rates. Industry reports highlight patient-friendly designs, improved biocompatibility, and longer dwell-time cannulas as key innovation areas. Development of anti-thrombogenic and infection-resistant coatings is expanding clinical acceptance. For instance, in February 2026, Johnson & Johnson launched CEREGLIDE 42, CEREGLIDE 57 aspiration catheters, and INNERGLIDE 7 delivery aid in the U.S. These devices expand its aspiration-first stroke portfolio and support distal clot removal. For the angiostomy cannula market, the launch signals stronger adoption of smaller, navigable, procedure-simplifying endovascular access systems. (Source: Johnson & Johnson)
Rapid healthcare infrastructure development and rising surgical volumes are creating new demand centers. India and Asia-Pacific are identified as high-growth regions for cannula adoption due to increasing procedures and healthcare access expansion. Government investments in hospital infrastructure are accelerating device penetration. The increasing prevalence of cardiovascular diseases continues to expand the patient pool requiring surgical intervention. CDC data reports 38.4 million people in the U.S. have diabetes (2024 update), a major risk factor for vascular complications
|
Current Event |
Description and its Impact |
|
FDA Expansion of Breakthrough Devices Program for Cardiovascular Technologies (2026) |
|
|
EU MDR Implementation Support Strengthens Medical Device Approvals (2026) |
|
|
India Expands Ayushman Bharat Healthcare Infrastructure Program (2026) |
|
|
China Accelerates Hospital Modernization and Cardiac Care Capacity Expansion (2026) |
|
|
U.S. Medicare Expands Reimbursement Support for Cardiovascular Procedures (2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The cardiac cannula segment is expected to dominate the market. This is because cardiac cannulas are easy to transport and easy to use. The cardiac cannula segment dominates the global angiostomy cannula market due to its critical use in cardiopulmonary bypass, CABG, valve replacement, congenital heart defect repair, and complex open-heart procedures. AHA’s January 2026 update reported 130.6 million U.S. adults with CVD, while CHD accounted for 38.2% of CVD deaths. The Heart Surgery Forum’s January 2026 review noted 161,907 CABG operations in the U.S. in 2023. Since CPB procedures require arterial and venous cannulas for perfusion and blood drainage, high cardiac surgery volumes continue to support segment dominance. (Source: AHA; ecfr.gov)
To learn more about this report, Request Free Sample
The cardiovascular surgery segment is expected to dominate the market over the forecast period and this is attributed to increasing prevalence of cardiovascular diseases like ischemic heart diseases around the world. Cardiovascular surgery dominates the global angiostomy cannula market because cannulas are indispensable in cardiopulmonary bypass, supporting venous drainage and arterial perfusion during open-heart and minimally invasive cardiac procedures. Demand is backed by high disease burden: AHA’s January 2026 update reported 915,973 U.S. CVD deaths in 2023, including 349,470 coronary heart-disease deaths. A March 2026 Journal of Clinical Medicine study involving 139 minimally invasive cardiac-surgery patients further highlights dependence on cannulation strategy. (Source: American Heart Association; NCBI; ResearchGate)
Based on End user, the global angiostomy cannula market is segmented into hospitals, ambulatory surgical centers, blood banks, and home healthcare facilities. The hospital segment is expected to dominate the market over the forecast period and this is due to the increasing hospitalizations for the treatment of trauma cases requiring major surgeries. The hospital segment dominates the global angiostomy cannula market due to the high concentration of complex cardiovascular surgeries, trauma care, and intensive care procedures requiring continuous vascular access and cardiopulmonary support. According to the American Heart Association (2026 Heart Disease & Stroke Statistics Update), cardiovascular diseases remain the leading cause of death in the U.S., driving high hospitalization rates for interventions such as CABG, valve repair, and ECMO support procedures. The CDC (2024–2026 cardiovascular facts update) reports that CVD causes nearly 1 in 3 deaths annually in the U.S., reinforcing hospital-based procedural dependency. In addition, FMI (2026) indicates that hospitals account for approximately 42.0% of total medical cannula end-user demand, primarily due to centralized surgical infrastructure and critical care units. The American Heart Association further highlights that advanced cardiac procedures increasingly require specialized perfusion systems and cannulation support, which are predominantly available in tertiary and quaternary hospital settings. High patient inflow, availability of skilled cardiothoracic surgeons, and adoption of ECMO and cardiopulmonary bypass technologies collectively strengthen hospital dominance in angiostomy cannula utilization. (Source: America Heart Association; CDC)
Key players around the world are enaging in inorganic strategies like mergers and acquisitions to help propel the rowth of the global angiostomy cannula market. For instance, in January 2022, ICU Medical Inc., a company focused on providing IV therapy, announced that it had completed its acquisition of Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. The acquisition was made to expand ICU Medical Inc.’s product portfolio.
In June 2021, Bidibots Pty Ltd, an Australia-based company focusing on providing quality paediatric and neonatal products into hospitals for the improvement of quality of care for our most vunerable children, developed the Bidibot, a new nasal cannula designed to sit comfortably on a baby’s face, overcoming the common risks associated with regular cannulas.
Arterial cannulation can be associated with bleeding, cannula malposition causing selective cerebral perfusion, plaque dislodgement, and dissection. Dissection presents as low arterial pressure, high arterial line pressure, loss of venous return, and bluish discolouration of the vessel. Venous cannulation can be associated with bleeding, cannula malposition/air lock causing an inadequate return, leading to cerebral, splanchnic congestion or massive air embolisms. This can restrain the growth of the global angiostomy cannula market.
Cessation of the pump and commencing retrograde cerebral perfusion can be used as a treatment, acting as a counterbalance against the given restraint.
To learn more about this report, Request Free Sample
North America is the dominant region in the Angiostomy Cannula Market acquiring a share of 45.6% due to its high cardiovascular disease burden, strong hospital infrastructure, advanced cardiac surgery ecosystem, and faster adoption of regulated medical devices. In the U.S., cardiovascular disease caused 919,032 deaths in 2023, equal to 1 in every 3 deaths, while heart disease care and medication costs exceeded US$168 billion during 2021–2022. The region also has a large procedure base, with the STS cardiac surgery registry covering nearly 10 million procedures, 4,300+ surgeons, and about 95% of adult cardiac surgery procedures. Strong hospital capacity further supports cannula use, as the U.S. had 6,100 hospitals, 907,216 staffed beds, and 35.6 million admissions in the 2026 AHA hospital statistics. High healthcare spending, including US$1.63 trillion in hospital expenditure in 2024, also supports premium cannula adoption. (Sources: CDC; STS National Database; AHA; cms.gov)
Asia Pacific is the fastest-growing region in the Angiostomy Cannula Market due to a combination of rising disease burden, expanding healthcare infrastructure, and strong government investment in medical technology. The region is experiencing a rapid increase in chronic diseases such as cardiovascular disorders and diabetes, driven by aging populations and lifestyle changes. In addition, governments across China, India, and Southeast Asia are heavily investing in hospital expansion and healthcare access, boosting demand for surgical consumables and minimally invasive devices. In 2026, the region is witnessing a significant surge in healthcare investments, with India allocating over ₹90,000 crore (~USD 10.8 billion) to healthcare and medical infrastructure development, strengthening tertiary care and surgical capacity. China has also expanded its hospital network to more than 36,000 hospitals, improving access to cardiovascular procedures and critical care services across urban and semi-urban regions.
Major players operating in the global angiostosmy cannula market include Smith+Nephew, Maquet Holding B.V. & Co. KG. (A subsidiary of Getinge), LivaNova PLC (Formed from the merger of Sorin group and Cyberonics, Inc.), Edwards Lifesciences Corporation, Medtronic, Merck & Co., Inc., Terumo Corporation, Medline Industries, LP, Cardinal Health, Boston Scientific Corporation, Teleflex Incorporated, Dolphin surgical industries, Goodhealth Inc., and BioTek Instruments, Inc. (A subsidiary of Agilent Technologies, Inc.)
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 216.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.1% | 2033 Value Projection: | USD 350.2 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Smith+Nephew, Maquet Holding B.V. & Co. KG. (A subsidiary of Getinge), LivaNova PLC (Formed from the merger of Sorin group and Cyberonics, Inc.), Edwards Lifesciences Corporation, Medtronic, Merck & Co., Inc., Terumo Corporation, Medline Industries, LP, Cardinal Health, Boston Scientific Corporation, Teleflex Incorporated, Dolphin surgical industries, Goodhealth Inc., BioTek Instruments, Inc. (A subsidiary of Agilent Technologies, Inc.) |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Increasing number of product approvals from regulatory agencies of respective countries are expected to boost the growth of the global angiostosmy cannula market over the forecast period. For instance, in April 2021, BD, a global medical technology company, announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Pristine Long-Term Hemodialysis Catheter, a new hemodialysis catheter with a unique side-hole free symmetric Y-Tip distal lumen design. The Pristine Catheter was made available in the U.S. in May 2021.
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
